Madhavan Balachandran
Known title: DirectorCIK: 0001555508
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Stevanato Group joins Ensera alliance with medical device partners. Stevanato Group has joined a new alliance network led by Ensera, alongside partners like SHL Medical and Ypsomed. This move aims to strengthen collaboration within the medical device supply chain. The stock is currently trading near its support level, with an average analyst target of $24.68.
Transaction History
| QURE | ▲ Buy | Option Exercise | 5,295 | $168K | 6/17/2026 | View on chart |
| QURE | ▲ Buy | Option Exercise | 6,390 | $124K | 6/17/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 5,295 | $249K | 6/17/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 4,700 | $205K | 6/17/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 1,690 | $72K | 6/17/2026 | View on chart |
| STVN | ▼ Sell | Open Market | 1,493 | $26K | 6/15/2026 | View on chart |
| QURE | ▲ Buy | Option Exercise | 10,000 | $85K | 6/15/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 10,000 | $279K | 6/15/2026 | View on chart |
| STVN | ▲ Buy | Grant | 4,975 | $0 | 6/12/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 1,993 | $54K | 6/11/2026 | View on chart |
| QURE | ▲ Buy | Grant | 7,550 | $0 | 6/10/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 2,112 | $31K | 6/20/2025 | View on chart |
| QURE | ▲ Buy | Grant | 7,970 | $0 | 6/11/2025 | View on chart |
| QURE | ▲ Buy | Grant | 8,080 | $0 | 6/19/2024 | View on chart |
| QURE | ▼ Sell | Open Market | 2,231 | $11K | 6/13/2024 | View on chart |
| QURE | ▼ Sell | Open Market | 2,283 | $43K | 6/16/2023 | View on chart |
| QURE | ▲ Buy | Grant | 8,700 | $0 | 6/13/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 384 | $8K | 2/27/2023 | View on chart |
| QURE | ▲ Buy | Grant | 9,080 | $0 | 6/15/2022 | View on chart |
| QURE | ▼ Sell | Open Market | 602 | $10K | 2/28/2022 | View on chart |
| QURE | ▲ Buy | Grant | 1,534 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
QURE shares fall after Huntington data update and Barclays downgrade
Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.
QURE shares fall after Huntington data update and Barclays downgrade. Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.